[Hiring] Senior Manager, Interactive Response Technology @BioMarin Pharmaceutical Inc.

Role Description

BioMarin is engaging a hands-on Interactive Response Technology (IRT) Lead to own the design, build, implementation, and lifecycle management of IRT/RTSM (randomization and trial supply management) systems across Phase I–IV clinical trials, including the integrations that connect them to adjacent clinical and enterprise platforms. This is an individual contributor engagement: the person in this seat does the work, rather than directing a team that does it.

The role sits at the intersection of Clinical Supply Chain, Global Study Operations, IT, and Supply Chain Strategy & Excellence, and carries end-to-end responsibility for IRT across the trial portfolio. Day to day, that means making sure patient randomization and investigational product handling run cleanly at the study level. Over the course of the engagement, it also means raising the standard — building the templates/standards, governance routines, and best practices that let IRT scale beyond any single trial. Success depends as much on cross-functional influence as on technical depth.

This is a contract position. The IRT Lead partners closely with internal stakeholders and external vendors, but does not manage BioMarin employees.

Responsibilities

• Serve as project manager for IRT on each assigned trial, leading study builds and support from kickoff through close-out, and holding both the vendor and the internal team to the study timeline.
• Partner with IT and study teams to translate protocols into User Requirement Specifications (URS), confirming that the randomization design, visit schedule, dosing regimens, stratification factors, unblinding rules, and drug supply configuration are captured accurately before the build begins.
• Act as the primary liaison to external IRT vendors, managing build timelines and deliverables, and overseeing configuration of study-specific modules against the approved specification.
• Develop test plans with IT and orchestrate cross-functional User Acceptance Testing (UAT) covering all requirements defined in the URS, including drug resupply, reports, and system integrations, with every defect documented and resolved before go-live.
• Coordinate training and system access for site staff, monitors, and study teams, verifying that blinded and unblinded roles are correctly assigned before first patient in.
• Provide day-to-day oversight during trial conduct: monitor enrollment and inventory through IRT dashboards, troubleshoot enrollment, dosing, and inventory issues with vendors and global study operations (GSO).
• Act as the Clinical Supply Chain (CSC) single point of contact for all IRT-related activities, representing CSC in cross-functional discussion.
• Continuously refine the IRT resupply parameters with Clinical Supply Chain (CSC) to prevent site stock-outs and reduce overages.
• Manage mid-study changes through formal change control process for protocol amendments by assessing cross-functional impact, updating specifications, retesting, and securing approvals and budget allocation before implementation.
• Lead IRT close-out alongside IT: database lock, IRT-to-EDC reconciliation, final investigational product accountability, data archival, and formal system decommissioning.
• Own IRT and RTSM as a business process for the organization: maintain the standard operating procedures, work instructions, IRT standards, test scripts, and training materials.
• Partner with the Head of Digital & Analytics in Supply Chain Strategy & Excellence to shape the IRT digital roadmap.
• Define the multi-year direction for IRT capability, assessing emerging features such as platform integrations, direct-to-patient supply, drug pooling, and adaptive randomization.
• Lead IRT vendor sourcing activities, including participation in RFQs/RFPs, vendor assessments, feasibility evaluations, and study-specific platform selection.
• Serve as the organization's subject matter expert on IRT, coaching study teams and partnering with Clinical Operations on randomization and blinding design.
• Define and report functional KPIs — system uptime, randomization error rate, site stock-out events, drug wastage.
• Represent IRT in cross-functional forums so that randomization and trial supply implications are weighed during protocol feasibility, risk management, and digital trial initiatives.

Qualifications

• Bachelor's degree in life sciences, engineering, supply chain, information systems, or a related field.
• Five or more years in clinical supply chain, clinical operations, or clinical systems, including at least five years of hands-on IRT or RTSM ownership across multiple concurrent studies.
• Demonstrated end-to-end delivery of IRT builds: specification authoring, test leadership, go-live, study operations and support, mid-study change control, and close-out reconciliation.
• Working knowledge of randomization and blinding methodology, clinical demand forecasting, and IRT resupply algorithms.
• Proven experience managing external IRT vendors, including timeline, deliverables, quality, and escalation management.
• Familiarity with GCP, 21 CFR Part 11, computer system validation, and inspection readiness expectations for clinical systems.
• Ability to work independently across global time zones, with the judgment to escalate early and the communication skills to align functions that do not report to this role.

Requirements

• Hands-on experience with more than one commercial IRT or RTSM platform.
• Rare disease, gene therapy, or global multi-region trial experience.
• Exposure to direct-to-patient supply models, decentralized trials, or adaptive designs.
• Experience with IRT integrations to EDC, CTMS, and ERP or supply planning systems.

Company Description

BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions. Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997.

Our revolutionary treatments for conditions like achondroplasia, PKU, CLN2, and a number of forms of MPS offer new possibilities for patients and families who previously had few, if any, available options.

Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities.